Abstract:Background: A reliable laboratory test to monitor on-clopidogrel platelet reactivity (PR) is very necessary. In addition, genetic factors also play an important part in on-clopidogrel PR. This study aimed to modify the original impedance whole blood platelet aggregation assay associated with the release assay to monitor on-clopidogrel PR and assess their relationship with genotype.Methods: We adjusted the concentration of calcium in the in vitro reaction system of platelet aggregation to modify the original impedance whole blood platelet aggregation assay. Meanwhile, chronolume, which quantified the adenosine triphosphate (ATP) released from platelet dense granules, is added to this reaction system to reflect the platelet release function. In the modified assay, platelet magnified activation time (MAT) and the maximal platelet ATP release value (RV) were used to reflect platelet function parameters. In the original assay, the electrical resistance (51) and RV were used to reflect platelet function parameters. On-clopidogrel PR was detected by the original impedance whole blood platelet aggregation assay, modified assay, and flow cytometric vasodilator stimulated phosphoprotein (VASP) assay in 168 patients with acute coronary syndromes (ACS). CYP2C19*2 and CYP2C19*3 polymorphisms were also detected in all of these patients.Results: This modified method showed that when 12.5 mu L CaCl2 (0.2 mmol/L) was added to the reaction system, MAT was appropriate (93 23 seconds). The CVs for the modified impedance assay and release assay were 9.31% and 6.13%, respectively. The mean VASP-PRI in the patient group treated with clopidogrel was significantly lower than that in the control group without antiplatelet therapy (54.88 +/- 16.81% vs. 79.86 +/- 10.24%, p < 0.001). MAT of the modified method in VASP PRI > 50% group were shorter than that in the PRI < 50% group [185 (154 - 241) vs. 214 (184 - 250), p < 0.05]. Meanwhile, the RV of the modified method in VASP PRI > 50% group were higher than that in the PRI < 50% group [1.00 (0.72 - 1.47) vs. 0.82 (0.62 - 1.08), p < 0.05]. However, the electrical resistance (Omega) and RV of the original method showed no differences between the two groups [0 (0 - 2) vs. 0 (0 - 1.25), 0.05 (0 - 0.25) vs. 0.08 (0 - 0.24); p > 0.05, p > 0.05, respectively). Moreover, neither the original method nor the modified method showed differences in patients with CYP2C19 (*2 and *3) wild type and mutant type.Conclusions: The consistency of the modified assay and VASP assay is good. The modified assay may be a potentially good laboratory method to monitor antiplatelet therapy.

Monitoring Residual Platelet Activity among Patients with Acute Coronary Syndrome.

Monitoring Residual Platelet Activity among Patients with Acute Coronary Syndrome Post-PCI by Modified Impedance Whole Blood Platelet Aggregation and Release Method

Baseline Platelet Count and Clinical Outcome in Acute Coronary Syndrome

Efficacy of Monitoring Platelet Function by an Automated PL-12 Analyzer During the Treatment of Acute Cerebral Infarction With Antiplatelet Medicine

Predictive Value of Antiplatelet Resistance on Early Stent Thrombosis in Patients with Acute Coronary Syndrome.

Residual Platelet Reactivity is Preferred over Platelet Inhibition Rate in Monitoring Antiplatelet Efficacy: Insights Using Thrombelastography

Quantifying the effect of antiplatelet therapy by whole blood platelet aggregometry

The Ratio of ADP- to TRAP-Induced Platelet Aggregation Quantifies P2Y12-Dependent Platelet Inhibition Independently of the Platelet Count

Low on-clopidogrel ADP- and TRAP-6-induced platelet aggregation in patients with atrial fibrillation undergoing percutaneous coronary intervention: an observational pilot study

Combination of P2Y12 Reaction Unit and Percentage of Platelet Inhibition Assessed by VerifyNow P2Y12 Assay is a Useful Predictor of Long-Term Clinical Outcomes in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

Measurement of platelet P-selectin for remote testing of platelet function during treatment with clopidogrel and/or aspirin

A platelet P-selectin test predicts adverse cardiovascular events in patients with acute coronary syndromes treated with aspirin and clopidogrel

Changes of Reticulated Platelets and Platelet Parameters in Acute Coronary Syndrome and Their Significance

Correlation Between Antiplatelet Resistance and Recurrent Cardiac Ischemic Events of Patients with Acute Myocardial Infarction

[Evaluation of a New Method and Instrument for Detection Platelet Aggregation Function and Its Clinical Application].

Platelet-fibrin Clot Strength Measured by Thromboelastography Could Predict Hypercoagulability and Antiplatelet Effects in Patients after Percutaneous Coronary Intervention.

Abstract 18394: Predicting Value of Platelet Reactivity on Bleeding and Major Adverse Cardiac Events in Eastern Asian PCI Patients

Abstract 13031: Real World Outcomes of Prognostic Value of Platelet Function Testing for Five-Year Ischemic Events in Patients Undergoing Percutaneous Coronary Intervention: A Large-Scale Cohort Study

Multi-parameter Assessment of Platelet Inhibition and Its Stability During Aspirin and Clopidogrel Therapy

The impact of residual platelet activity and CYP2C19 polymorphism on the prognosis of acute coronary syndrome patients

Comparison of Modified Impedance Whole Blood Platelet Aggregation Method Detecting Platelet Function in ACS Patients with Different CYP2C19 Genotypes